Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adstiladrin Phase 3 in BCG-Unresponsive NMIBC
NCT02773849Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- May 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nadofaragene firadenovec in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Ferring Pharmaceuticals. Primary endpoint: Complete Response Rate at 12 months. Started Sep 2016; status: completed.
02
Drugs
nadofaragene firadenovec
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02773849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02773849.